SCHEDULE: BlackRock Discloses 15.3% Stake in Myriad Genetics

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 15.3% beneficial ownership stake in Myriad Genetics Inc., totaling 14,105,009 shares of common stock.

Summary

• BlackRock, Inc. reported beneficial ownership of 14,105,009 shares of Myriad Genetics Inc. common stock.
• This represents 15.3% of the outstanding common stock of Myriad Genetics Inc.
• BlackRock holds sole voting power over 13,890,191 shares and sole dispositive power over 14,105,009 shares.
• The filing is an Amendment No. 4 to Schedule 13G.
• The event date requiring the filing is June 30, 2025, with the filing signed on July 17, 2025.
• The ownership is held in the ordinary course of business and not for the purpose of changing or influencing control of Myriad Genetics Inc.
• iShares Core S&P Small-Cap ETF and BlackRock Fund Advisors are identified as entities within BlackRock's structure that beneficially own more than 5% of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of a significant passive ownership stake by a major institutional investor, BlackRock, in Myriad Genetics Inc. While not indicating active management or control intent, a substantial holding by a firm like BlackRock can be viewed as a positive signal of confidence in the underlying company.

Positives

• BlackRock, a major institutional investor, holds a significant 15.3% stake, indicating substantial investment interest in Myriad Genetics Inc.

Negatives

• NA

Risks

• The securities were not acquired or held for the purpose of changing or influencing the control of Myriad Genetics Inc., as certified by BlackRock.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing represents a routine disclosure by a major asset manager, BlackRock, of its significant passive investment in a publicly traded company within the biotechnology and diagnostics sector, Myriad Genetics Inc. Such disclosures are common for large institutional investors managing diverse portfolios.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder, potentially influencing market perception.
• Management: Awareness of a large passive investor, but no direct impact on operations or strategy as the holding is not for control purposes.

Next Steps

• BlackRock, Inc. will continue to file amendments to Schedule 13G as required by SEC regulations if its beneficial ownership percentage changes significantly.

Key Dates

Recommendation

Keywords

Myriad Genetics, BlackRock, Schedule 13G, beneficial ownership, institutional investment, common stock, SEC filing, equity stake